Clinical trials: Herpes Simplex
Herpes Simplex, Pregnancy
A Study of HSV Testing Among Pregnant Women
The objective of the study is to evaluate the acceptance and effect of type- specific HSV serologic testing of pregnant women on sexual behavior at the end of pregnancy.
- Trial name
- NCT00194415
- Testing
- Safer-sex counseling, Type specific serologic HSV testing
- Where
- Canada
- Volunteers
- 173 people, healthy volunteers welcome
- Sponsor
- University of Washington
Herpes Zoster
Immunogenicity and Safety of SYS6052 in the Participants Aged 40 Years and Above
Herpes zoster is caused by the reactivation of latent varicella-zoster virus (VZV) which stays in latency after its primary infection. Immunosenescence contributes significantly to elevating morbidity associated with aging.
- Trial name
- NCT07892989
- Testing
- Recombinant Zoster Vaccine (CHO cell) SYS6052, Active Comparator Vaccine
- Volunteers
- 496 people, healthy volunteers welcome
- Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
Herpes Zoster
Safety and Immunogenicity Study of Live Attenuated Vaccine Against Herpes Zoster in Chinese Adults Aged 50 Years and Older
This study evaluates the safety and immunogenicity of live attenuated vaccine in adults aged 50 years and older. Half of participants will receive high doses of the vaccine,while the other half will receive low doses of the…
- Trial name
- NCT02526745
- Testing
- the vaccine with high doses of virus content between 4.7～5.0 lgPFU, the vaccine with low doses of virus content between 4.7～5.0 lgPFU, the vaccine with high doses of virus content between 4.3～5.0 lgPFU
- Volunteers
- 440 people, healthy volunteers welcome
- Sponsor
- Beijing Chaoyang District Centre for Disease Control and Prevention
Herpes Zoster, Vaccine-Preventable Diseases
A Study to Evaluate Safety and Tolerability of a Recombinant Herpes Zoster Vaccine
This clinical trial is to study the safety and tolerability of a recombinant herpes zoster vaccine (LZ901) and sponsored by Beijing Luzhu Biotechnology Co., Ltd.
- Trial name
- NCT05750017
- Testing
- Low Dose Recombinant Herpes Zoster Vaccine (LZ901), High Dose Recombinant Herpes Zoster Vaccine (LZ901)
- Where
- United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Beijing Luzhu Biotechnology Co., Ltd.
Methicillin-Resistant Staphylococcus Aureus, Atopic Dermatitis
The Underlying Mechanisms For S. Aureus Infection And Colonization Of Skin in People With Atopic Dermatitis With And Without Eczema Herpeticum (MRSA)
Staphylococcus aureus (S.aureus) is a bacterium that causes many painful skin and soft tissue conditions, such as scalded-skin syndrome, boils, or impetigo.
- Conditions
- Methicillin-Resistant Staphylococcus Aureus, Atopic Dermatitis, Eczema Herpeticum, MRSA
- Trial name
- MRSA (NCT00822276)
- Where
- 2 sites in United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV
Optimization of the ex Vivo Challenge: Reproductive Infections and Contraception
The development of surrogates to predict HIV prevention product safety and efficacy is a high priority. An ex vivo challenge model is one such promising surrogate.
- Trial name
- NCT02375425
- Testing
- no intervention
- Where
- United States
- Volunteers
- 294 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Human Immunodeficiency Virus
Problems With Immune Recovery in the Gut Tissue
The aim of this study is to find out if the process of HIV replication in the lymph tissue and gut tissue of people taking HIV drugs causes long-term damage to the ability of the gut to protect you from other infections and…
- Trial name
- NCT01460433
- Testing
- Genital and rectal swabbing
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Genital Herpes Simplex Type 2
A Clinical Trial in Healthy Volunteers and Volunteers With Recurrent Genital Herpes to Study the Safety, Tolerability, and Immune Responses After Vaccination With an Investigational Vaccine Designed to Prevent Genital Herpes Lesions
This exploratory trial will have three parts. Part A is a dose escalation part, Part B is an expanded safety and dose evaluation part, and Part C is a safety and immunogenicity evaluation part in individuals with recurrent HSV-2…
- Trial name
- NCT05432583
- Testing
- BNT163
- Where
- 6 sites in United States
- Volunteers
- 318 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
Atopic Dermatitis
Identifying Genetic Determinants of Eczema Herpeticum and Other Viral Infections in Individuals With Atopic Dermatitis
People with atopic dermatitis (AD), or eczema, are susceptible to skin infections and inflammations. Some individuals with AD develop a condition known as eczema herpeticum (EH) following exposure to the herpes simplex virus…
- Trial name
- Genetics (NCT00515047)
- Where
- 7 sites in United States
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Herpes Zoster, Herpes Zoster Vaccine
Consistency, Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults ≥ 50 Years of Age
The purpose of this study is to demonstrate lot-to-lot consistency in terms of immunogenicity, and evaluate safety of the Herpes Zoster subunit (HZ/su) vaccine.
- Trial name
- NCT02075515
- Testing
- Herpes Zoster vaccine (GSK 1437173A)
- Where
- 8 sites in United States, Belgium and 1 more
- Volunteers
- 651 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Herpes Zoster
Month 30 & 42 Extension Studies of CRD-004 Primary Study
The safety and immunogenicity of the GSK324332A vaccine has been evaluated up to Month 12 post-vaccination in the primary study.
- Trial name
- NCT00492648
- Testing
- Blood sampling for assay of persistence of immunogenicity
- Where
- Belgium
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy
Drug-Drug Interaction Study: ASP2151 and Ciclosporin
ASP2151 is an experimental treatment for herpes. Patients undergoing organ and tissue transplantation may be prescribed ciclosporin to suppress their immune system to give the transplant an increased chance of not being rejected.
- Trial name
- NCT02280421
- Testing
- ASP2151 400mg + 100mg ciclosporin, ASP2151 1200mg + 100mg ciclosporin
- Where
- United Kingdom
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Maruho Europe Limited
Acute Bacterial Infections, Acute Viral Infections
300 Antibody Diagnostic Test Kit
For the development of a Point of Care IVD test kit for acute phase disease detection against a variety of bacterial and viral infections.
- Trial name
- Antibody 300 (NCT01646411)
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- The Plasma Source
Atopic Dermatitis, Eczema Herpeticum
Identifying Risk Factors for Eczema Herpeticum in Individuals With Atopic Dermatitis
Atopic Dermatitis (AD), also known as eczema, is a skin disease that causes the skin to be hot, dry and scaly, and have severe itching. There are different kinds of eczema.
- Trial name
- NCT00438022
- Where
- Germany
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Herpes Zoster, Inflammatory Bowel Diseases
Identifying Young Inflammatory Bowel Disease Patients at Risk for Herpes Zoster
Inflammatory bowel disease (IBD) patients under the age of 50 can have a greater risk than the general population above age 50. IBD patient are commonly treated with immunosuppression that increases the risk for Herpes Zoster.
- Conditions
- Herpes Zoster, Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
- Trial name
- NCT03553472
- Where
- United States
- Volunteers
- 97 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Herper Zoster
Biomarker Study in Patients With Herpes Zoster
Investigators performed this study to investigate the expression levels inflammatory cytokine and neurotransmitters (calcitonin gene-related peptide (CGRP), substance P (SP), vasoactive intestinal peptide (VIP), and β-endorphin)…
- Trial name
- NCT05685797
- Testing
- Herpes zoszter (acute)with inter vention
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Keimyung University Dongsan Medical Center
Cutaneous Manifestations, Skin Manifestations
Cutaneous Manifestations of Coronavirus Disease 2019(COVID-19).
An outbreak of Corona virus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-coV-2) occurred in Wuhan city, Hubei province, China in December 2019.
- Conditions
- Cutaneous Manifestations, Skin Manifestations, COVID-19, COVID-19 Pneumonia
- Trial name
- NCT05094687
- Where
- Pakistan
- Volunteers
- 1,206 people, healthy volunteers welcome
- Sponsor
- Jinnah Postgraduate Medical Centre
Genital Herpes Simplex Type 2
Safety and Efficacy Trial of DNA Vaccines to Treat Genital Herpes in Adults
The purpose of this study is to test the safety and effectiveness of two experimental therapeutic vaccines against herpes simplex virus, type 2 (HSV-2).
- Trial name
- NCT02030301
- Testing
- VCL-HB01, VCL-HM01, PBS
- Where
- 7 sites in United States
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- Vical
Virus, HSV-1
Hand Sanitizer Use for Herpes Simplex Virus-1
The purpose of this pilot study is to determine if the use of Purell hand sanitizer alters the duration, level of pain and discomfort during treatment, and the size of the HSV-1 lesion.
- Conditions
- Virus, HSV-1, Herpes Simplex 1, Herpes Simplex Labialis
- Trial name
- NCT06135844
- Testing
- Purell Hand Sanitizer, Medical Grade Mineral Oil
- Where
- 3 sites in United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Leciel Bono
Herpes Simplex Type Two Infection, HIV Infections
Examining the Ability of Herpes Simplex Virus Type 2 (HSV2) Therapy to Reduce HIV Target Cell Numbers in the Cervix
Herpes simplex virus type 2 (HSV2), the most common cause of genital herpes, increases a woman's risk of HIV acquisition from 3-6 fold, perhaps because HSV2-infected women have increased numbers of HIV "target cells" (CD4 T cells…
- Trial name
- NCT00946556
- Testing
- Valacyclovir
- Where
- Canada
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Toronto